Shah, Parth <br/><br/>
Efficacy, safety, Low density lipoprotein cholesterol lowering, and calculated 10-year cardiovascular risk reduction of alirocumab and evolocumab in addition to maximal tolerated cholesterol lowering therapy: a post-commercialization study.  [electronic resource] 

 -  Lipids in health and disease  Jan 2017 
 - 19 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1476-511X 
<br/><br/><label>Standard No.: </label>10.1186/s12944-017-0416-7  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Antibodies, Monoclonal--administration & dosage<br/>Antibodies, Monoclonal, Humanized<br/>Anticholesteremic Agents--administration & dosage<br/>Cardiovascular Diseases--blood<br/>Cholesterol, LDL--blood<br/>Female<br/>Humans<br/>Hypercholesterolemia--blood<br/>Male<br/>Maximum Tolerated Dose<br/>Middle Aged<br/>Risk Factors<br/>Treatment Outcome